Literature DB >> 26336886

Neutrophilic leukocytosis in advanced stage polycythemia vera: hematopathologic features and prognostic implications.

Leonardo Boiocchi1,2, Umberto Gianelli2, Alessandra Iurlo3, Falko Fend4, Irina Bonzheim4, Daniele Cattaneo3, Daniel M Knowles1, Attilio Orazi1.   

Abstract

Polycythemia vera in 20-30% of cases progresses towards post-polycythemic myelofibrosis, an advanced phase characterized by decreased red blood cells counts and increasing splenomegaly with extramedullary hematopoiesis. There is evidence that the presence of neutrophilic leukocytosis at polycythemia vera disease outset is associated with an increased risk of recurrent thrombosis. However, its clinical significance when developing later in the course of the disease is not well defined. Over a period of 8 years we identified from the files of two reference centers 10 patients (7M/3F, median age: 68 years) who developed persistent absolute leukocytosis ≥ 13 × 10⁹/l (median: 25.1 × 10⁹/l; range: 16.1-89.7 × 10⁹/l) at or around the time of diagnosis of post-polycythemic myelofibrosis (median interval from diagnosis:0 months; range: -6/31) and persisted for a median period of 13 months. Peripheral blood smears showed numerous neutrophils without dysplastic features and, in four, ≥ 10% immature myeloid precursors. In five cases, corresponding marrow specimens obtained at or immediately after the onset of leukocytosis showed a markedly increased myeloid:erythroid ratio due to granulocytic proliferation. No change in JAK2 and BCR-ABL1 status or cytogenetic evolution was associated with the development of leukocytosis. The mutational status of CSF3R, SETBP1, and SRSF2, genes associated with other chronic myeloid neoplasms where neutrophilic leukocytosis occurs, was investigated but all cases showed wild-type only alleles. Four patients died after developing leukocytosis and one experienced worsening disease. Compared with a control group of post-polycythemic myelofibrosis patients (n=23) who never developed persistent leukocytosis, patients with leukocytosis showed higher white blood cells counts and a shorter overall survival. This is the first study describing the development of significant neutrophilic leukocytosis during advanced stages of polycythemia vera; it includes comprehensive hematologic, marrow morphological, molecular, and clinical data. Our findings suggest that persistent leukocytosis occurring at or around the time of progression to post-polycythemic myelofibrosis is associated with an overall more aggressive course of the disease.

Entities:  

Mesh:

Year:  2015        PMID: 26336886     DOI: 10.1038/modpathol.2015.100

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  30 in total

1.  Perspectives on thrombosis in essential thrombocythemia and polycythemia vera: is leukocytosis a causative factor?

Authors:  Tiziano Barbui; Alessandra Carobbio; Alessandro Rambaldi; Guido Finazzi
Journal:  Blood       Date:  2009-04-16       Impact factor: 22.113

Review 2.  The molecular genetics of chronic neutrophilic leukaemia: defining a new era in diagnosis and therapy.

Authors:  Michelle A Elliott; Ayalew Tefferi
Journal:  Curr Opin Hematol       Date:  2014-03       Impact factor: 3.284

Review 3.  Bone marrow histopathology in myeloproliferative disorders--current diagnostic approach.

Authors:  Juergen Thiele; Hans Michael Kvasnicka; Attilio Orazi
Journal:  Semin Hematol       Date:  2005-10       Impact factor: 3.851

4.  Mutations in SETBP1 are recurrent in myelodysplastic syndromes and often coexist with cytogenetic markers associated with disease progression.

Authors:  Marta Fernandez-Mercado; Andrea Pellagatti; Cristina Di Genua; Maria Jose Larrayoz; Nils Winkelmann; Paula Aranaz; Adam Burns; Anna Schuh; Maria Jose Calasanz; Nicholas C P Cross; Jacqueline Boultwood
Journal:  Br J Haematol       Date:  2013-07-24       Impact factor: 6.998

5.  Evaluation of WHO criteria for diagnosis of polycythemia vera: a prospective analysis.

Authors:  Richard T Silver; William Chow; Attilio Orazi; Stephen P Arles; Stanley J Goldsmith
Journal:  Blood       Date:  2013-07-30       Impact factor: 22.113

Review 6.  Impact of bone marrow pathology on the clinical management of Philadelphia chromosome-negative myeloproliferative neoplasms.

Authors:  Olga Pozdnyakova; Robert P Hasserjian; Srdan Verstovsek; Attilio Orazi
Journal:  Clin Lymphoma Myeloma Leuk       Date:  2014-11-18

7.  Proposed criteria for the diagnosis of post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a consensus statement from the International Working Group for Myelofibrosis Research and Treatment.

Authors:  G Barosi; R A Mesa; J Thiele; F Cervantes; P J Campbell; S Verstovsek; B Dupriez; R L Levine; F Passamonti; J Gotlib; J T Reilly; A M Vannucchi; C A Hanson; L A Solberg; A Orazi; A Tefferi
Journal:  Leukemia       Date:  2007-08-30       Impact factor: 11.528

8.  Leucocytosis in polycythaemia vera predicts both inferior survival and leukaemic transformation.

Authors:  Naseema Gangat; Jacob Strand; Chin-Yang Li; Wenting Wu; Animesh Pardanani; Ayalew Tefferi
Journal:  Br J Haematol       Date:  2007-08       Impact factor: 6.998

9.  Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia.

Authors:  Francesco Passamonti; Elisa Rumi; Ester Pungolino; Lucia Malabarba; Paola Bertazzoni; Marina Valentini; Ester Orlandi; Luca Arcaini; Ercole Brusamolino; Cristiana Pascutto; Mario Cazzola; Enrica Morra; Mario Lazzarino
Journal:  Am J Med       Date:  2004-11-15       Impact factor: 4.965

10.  Morphologic and cytogenetic differences between post-polycythemic myelofibrosis and primary myelofibrosis in fibrotic stage.

Authors:  Leonardo Boiocchi; Susan Mathew; Umberto Gianelli; Alessandra Iurlo; Tommaso Radice; Sharon Barouk-Fox; Daniel M Knowles; Attilio Orazi
Journal:  Mod Pathol       Date:  2013-06-21       Impact factor: 7.842

View more
  5 in total

Review 1.  Nuances of Morphology in Myelodysplastic Diseases in the Age of Molecular Diagnostics.

Authors:  Aaron C Shaver; Adam C Seegmiller
Journal:  Curr Hematol Malig Rep       Date:  2017-10       Impact factor: 3.952

2.  Disease progression in myeloproliferative neoplasms: comparing patients in accelerated phase with those in chronic phase with increased blasts (<10%) or with other types of disease progression.

Authors:  Julia T Geyer; Elizabeth Margolskee; Spencer A Krichevsky; Daniele Cattaneo; Leonardo Boiocchi; Paola Ronchi; Francesca Lunghi; Joseph M Scandura; Maurilio Ponzoni; Robert P Hasserjian; Umberto Gianelli; Alessandra Iurlo; Attilio Orazi
Journal:  Haematologica       Date:  2019-09-19       Impact factor: 9.941

3.  Ruxolitinib for refractory/relapsed hemophagocytic lymphohistiocytosis.

Authors:  Jingshi Wang; Yini Wang; Lin Wu; Xinkai Wang; Zhili Jin; Zhuo Gao; Zhao Wang
Journal:  Haematologica       Date:  2019-09-12       Impact factor: 9.941

4.  The ABNL-MARRO 001 study: a phase 1-2 study of randomly allocated active myeloid target compound combinations in MDS/MPN overlap syndromes.

Authors:  Tamara K Moyo; Jason H Mendler; Raphael Itzykson; Ashwin Kishtagari; Eric Solary; Adam C Seegmiller; Aaron T Gerds; Gregory D Ayers; Amy E Dezern; Aziz Nazha; Peter Valent; Arjan A van de Loosdrecht; Francesco Onida; Lisa Pleyer; Blanca Xicoy Cirici; Raoul Tibes; Klaus Geissler; Rami S Komrokji; Jing Zhang; Ulrich Germing; David P Steensma; Daniel H Wiseman; Michael Pfeilstöecker; Chiara Elena; Nicholas C P Cross; Jean-Jacques Kiladjian; Michael Luebbert; Ruben A Mesa; Guillermo Montalban-Bravo; Guillermo F Sanz; Uwe Platzbecker; Mrinal M Patnaik; Eric Padron; Valeria Santini; Pierre Fenaux; Michael R Savona
Journal:  BMC Cancer       Date:  2022-09-24       Impact factor: 4.638

Review 5.  Progression of Myeloproliferative Neoplasms (MPN): Diagnostic and Therapeutic Perspectives.

Authors:  Julian Baumeister; Nicolas Chatain; Alexandros Marios Sofias; Twan Lammers; Steffen Koschmieder
Journal:  Cells       Date:  2021-12-16       Impact factor: 6.600

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.